Comparative Review of the Carbapenems

被引:0
|
作者
George G. Zhanel
Ryan Wiebe
Leanne Dilay
Kristjan Thomson
Ethan Rubinstein
Daryl J. Hoban
Ayman M. Noreddin
James A. Karlowsky
机构
[1] University of Manitoba,Department of Medical Microbiology, Faculty of Medicine
[2] University of Manitoba,Department of Medicine
[3] Health Sciences Center,Department of Clinical Microbiology
[4] University of Minnesota,College of Pharmacy
[5] Health Sciences Centre,MS 673 Microbiology
来源
Drugs | 2007年 / 67卷
关键词
Imipenem; Meropenem; Cefepime; Nosocomial Pneumonia; Ertapenem;
D O I
暂无
中图分类号
学科分类号
摘要
The carbapenems are β-lactam antimicrobial agents with an exceptionally broad spectrum of activity. Older carbapenems, such as imipenem, were often susceptible to degradation by the enzyme dehydropeptidase-1 (DHP-1) located in renal tubules and required co-administration with a DHP-1 inhibitor such as cilastatin. Later additions to the class such as meropenem, ertapenem and doripenem demonstrated increased stability to DHP-1 and are administered without a DHP-1 inhibitor. Like all β-lactam antimicrobial agents, carbapenems act by inhibiting bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs). Carbapenems are stable to most β-lactamases including AmpC β-lactamases and extended-spectrum β-lactamases. Resistance to carbapenems develops when bacteria acquire or develop structural changes within their PBPs, when they acquire metallo-β-lactamases that are capable of rapidly degrading carbapenems, or when changes in membrane permeability arise as a result of loss of specific outer membrane porins.
引用
收藏
页码:1027 / 1052
页数:25
相关论文
共 50 条
  • [1] Comparative review of the carbapenems
    Zhanel, George G.
    Wiebe, Ryan
    Dilay, Leanne
    Thomson, Kristjan
    Rubinstein, Ethan
    Hoban, Daryl J.
    Noreddin, Ayman M.
    Karlowsky, James A.
    DRUGS, 2007, 67 (07) : 1027 - 1052
  • [2] Comparative Review of Analytical Techniques for Determination of Carbapenems
    Cielecka-Piontek, Judyta
    Michalska, Katarzyna
    Zalewski, Przemyslaw
    Zasada, Stefan
    CURRENT ANALYTICAL CHEMISTRY, 2012, 8 (01) : 91 - 115
  • [3] Comparative pharmacokinetics of the carbapenems - Clinical implications
    Mouton, JW
    Touw, DJ
    Horrevorts, AM
    Vinks, AATMM
    CLINICAL PHARMACOKINETICS, 2000, 39 (03) : 185 - 201
  • [4] Valproate Interaction With Carbapenems: Review and Recommendations
    Al-Quteimat, Osama
    Laila, Alla
    HOSPITAL PHARMACY, 2020, 55 (03) : 181 - 187
  • [5] Carbapenems against Mycobacterium tuberculosis: a review of the evidence
    Jaganath, D.
    Lamichhane, G.
    Shahs, M.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (11) : 1436 - 1447
  • [6] Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: A review
    Cometta, A
    Glauser, MP
    JOURNAL OF CHEMOTHERAPY, 1996, 8 (05) : 375 - 381
  • [7] Outpatient parenteral antimicrobial therapy with carbapenems: A systematic review
    Wolie, Z. T.
    Roberts, J. A.
    Wale, Y. M.
    Unwin, S.
    McCarthy, K.
    Sime, F. B.
    JOURNAL OF INFECTION, 2024, 89 (05)
  • [8] Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii
    Douraghi, M.
    Ghalavand, Z.
    Rostami, M. Nateghi
    Zeraati, H.
    Aliramezani, A.
    Rahbar, M.
    Mohammadzadeh, M.
    Ghourchian, S.
    Boroumand, M. A.
    Abdollahi, A.
    JOURNAL OF APPLIED MICROBIOLOGY, 2016, 121 (02) : 401 - 407
  • [9] Carbapenems
    Breilh, Dominique
    Texier-Maugein, Jeannette
    Allaouchiche, Bernard
    Saux, Marie-Claude
    Boselli, Emmanuel
    JOURNAL OF CHEMOTHERAPY, 2013, 25 (01) : 1 - 17
  • [10] A COMPARATIVE-STUDY ON THE CONVULSANT ACTIVITY OF CARBAPENEMS AND BETA-LACTAMS
    SHIMADA, J
    HORI, S
    KANEMITSU, K
    SHOJI, Y
    NAKASHIO, S
    YANAGAWA, A
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 1992, 18 (09) : 377 - 381